Greg Riggins, M.D., Ph.D.

Professor of Neurosurgery and Oncology, Johns Hopkins University School of Medicine

"The team at ABC2 has a risk-taking, can-do attitude when it comes to developing new treatments for brain cancer.  As a researcher, I like that in a teammate.  In fact, I chose to rappel 34 stories from the tallest building in San Diego to support their Over The Edge event - that would not have happened unless I truly believed in them!"

Greg is the inaugural Irving J. Sherman M.D. Research Professor of Neurosurgery and Oncology at Johns Hopkins University School of Medicine. There, he is the Director of the Brain Cancer Biology and Therapy Laboratory started in 2003, and also the Director of Research for the Division of Neurosurgery.

The Brain Cancer Biology and Therapy Laboratory is a translational cancer research lab focusing on glioblastoma and other brain tumors.  Dr. Riggins and his laboratory have helped develop experimental cancer therapies based on drug repurposing, drug combinations, novel targeted therapy, bacteria based immunotherapy, and cancer prevention.

So far, research from the Riggins lab has received approval for clinical trials including: 1) a phase 1 clinical trial for an improved formulation for mebendazole in combination with Temozolomide for newly diagnosed patients with glioblastoma and 2) a phase 1 trial for the novel procaspase 3 activator, PAC-1, (first developed at the University of Illinois) for newly diagnosed glioblastoma. 

In addition to these possible new therapies for glioblastoma, a major area of active research is the development of improved therapeutic approaches for IDH mutant progressive gliomas. 

Greg has also developed strategies for cancer prevention, for therapies affordable to underprivileged patients, and for those individuals at a very high risk for cancer.